GSK PLC Sponsored ADR $GSK Shares Purchased by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC raised its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 3.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,989 shares of the pharmaceutical company’s stock after purchasing an additional 388 shares during the quarter. Valeo Financial Advisors LLC’s holdings in GSK were worth $499,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of GSK. Brighton Jones LLC acquired a new stake in GSK during the 4th quarter valued at approximately $528,000. Rhumbline Advisers grew its stake in GSK by 2.1% during the 1st quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company’s stock valued at $713,000 after purchasing an additional 386 shares in the last quarter. Farther Finance Advisors LLC grew its stake in GSK by 50.1% during the 1st quarter. Farther Finance Advisors LLC now owns 6,085 shares of the pharmaceutical company’s stock valued at $230,000 after purchasing an additional 2,030 shares in the last quarter. GAMMA Investing LLC grew its stake in GSK by 107.8% during the 1st quarter. GAMMA Investing LLC now owns 4,447 shares of the pharmaceutical company’s stock valued at $172,000 after purchasing an additional 2,307 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in shares of GSK by 71.4% in the 1st quarter. SG Americas Securities LLC now owns 18,840 shares of the pharmaceutical company’s stock worth $730,000 after acquiring an additional 7,849 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Down 0.3%

Shares of GSK stock opened at $43.36 on Thursday. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $45.59. The stock has a market cap of $88.21 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 1.96 and a beta of 0.53. The business’s fifty day moving average is $40.08 and its 200-day moving average is $38.78. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $7.92 billion. During the same period last year, the firm earned $0.43 EPS. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be issued a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date is Friday, August 15th. GSK’s payout ratio is presently 77.78%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GSK. Weiss Ratings reiterated a “hold (c)” rating on shares of GSK in a research report on Wednesday. Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Seven equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.